checkAd

     153  0 Kommentare Achiko Partners with Udayana University for Covid-19 Testing Research in Bali, Indonesia - Seite 2

    The research findings are expected to become available within 3 months after launch of the study, serving as a reference point for governments and stakeholders when evaluating cross-border testing in Indonesia and beyond. Teman Sehat’s digital passport solution supports a wide range of testing solutions, including Gumnuts, and can be integrated into other digital passports such as the IATA Travel Pass and the World Economic Forum’s CommonPass.

    “Whilst the vaccine developments are promising, we firmly believe that vaccinations and testing go hand in hand. Mass testing and vaccination passports give people the tools to show their negative test results, allowing them to move freely within a secure environment,” said Steven Goh, CEO of Achiko. “We’re excited to be working with Udayana in Bali, a place we all love. The study will create a proof of concept that we hopefully will be able to extend to the rest of Indonesia, and to many other countries afflicted by the pandemic.”

    The Chairman of the Health Research Center at University Udayana, Dr. I Md Ady Wirawan, MPH, PhD, added: “We are looking forward to doing this research study with the Achiko team, allowing us to learn more about how mass diagnostic testing can assist the local government and stakeholders in combatting the Covid-19 pandemic.”

    About Achiko AG
    We create solutions with a great user experience, for the transformation of the healthcare industry.

    The development of our patent pending diagnostic testing kit for Covid-19 (Gumnuts) provides an easy and effective way to help people get the information they need. This is complemented by our mobile check-in app (Teman Sehat), enabling users to manage their diagnostic experiences on their own terms, safeguard their privacy, share experiences and find community.

    We are headquartered in Zurich, with offices in Hong Kong, Jakarta, Singapore and Seoul.
    http://www.achiko.com/

    Media contacts:

    ACHIKO AG
    Investor Relations
    E: ir@achiko.com

    Switzerland
    Marcus Balogh
    Farner Consulting Ltd.
    E: achiko@farner.ch
    T: +41 44 266 67 67

    Germany and Austria
    Axel Mühlhaus / Dr Sönke Knop
    edicto GmbH
    E: achiko@edicto.de
    T: +49 69 90 55 05-51

    DISCLAIMER
    This communication expressly or implicitly contains certain forward-looking statements concerning Achiko AG and its business. Such statements involve certain known and unknown risks, uncertainties and other factors, which could cause the actual results, financial condition, performance or achievements of Achiko AG to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. Achiko AG is providing this communication as of this date and does not undertake to update any forward-looking statements contained herein as a result of new information, future events or otherwise.


    Seite 2 von 2



    globenewswire
    0 Follower
    Autor folgen

    Verfasst von globenewswire
    Achiko Partners with Udayana University for Covid-19 Testing Research in Bali, Indonesia - Seite 2 Achiko signed a research agreement with Udayana University’s Research Department to study the practicability of a mass testing approach with Teman Sehat and Gumnuts when availableThe Study will focus on a systems approach to mass testing and …

    Schreibe Deinen Kommentar

    Disclaimer